Effects of glucagon‐like peptide‐1 receptor agonists on kidney function and safety in type 2 diabetes patients

Abstract

Glucagon‐like peptide‐1 receptor agonists have been recommended in diabetic kidney disease patients.

Updates of incretin‐related drugs for the treatment of type 2 diabetes

“…Besides the safety and efficacy of DPP‐4 inhibitors, meta‐analysis of randomized trials showed that glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) reduced the risk of major adverse cardiac events, all‐cause mortality, hospital admission for heart failure and the composite kidney outcome, without an increase of adverse effects 10 . In addition to the protective effects on cardiovascular diseases and kidney function 11 , GLP‐1 RAs can reduce bodyweight 12 .…”